The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). The main questions it aims to answer are: Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions. Participants will: Provide retrospective clinical, pathological, and metabolic data from hospital records. Have survival and recurrence outcomes assessed through follow-up data review.
Study Type
OBSERVATIONAL
Enrollment
600
Qilu Hospital of Shandong University
Jinan, Shandong, China
Overall Survival
Time frame: From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years
Disease-specific survival
Time frame: From date of diagnosis until death due to PanNETs, up to 12 years
Progression-free survival
Time frame: From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.
Disease-free survival
Time frame: From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.